|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
1,430,000,000 |
Market
Cap: |
110.27(B) |
Last
Volume: |
6,919,020 |
Avg
Vol: |
8,403,954 |
52
Week Range: |
$48.64 - $76.12 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 297 |
Guru Rank Value : 4.1 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Boston Scientific develops, manufactures and markets medical devices. Co.'s Medical Surgical segment consist of: Endoscopy, which develops and manufactures devices to diagnose and treat a range of gastrointestinal and pulmonary conditions; and Urology and Pelvic Health, which develops and manufactures devices to treat various urological and pelvic conditions. Co.'s Rhythm and Neuro segment includes: Cardiac Rhythm Management, which develops and manufactures implantable devices to treat cardiac abnormalities; and Electrophysiology, which develops and manufactures medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
319,019 |
515,317 |
1,014,661 |
2,126,174 |
Total Sell Value |
$23,643,548 |
$35,409,189 |
$61,747,133 |
$111,248,213 |
Total People Sold |
9 |
10 |
11 |
13 |
Total Sell Transactions |
15 |
27 |
45 |
80 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Pucel Kenneth |
EVP, Global Ops & Technology |
|
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,792 |
95,516 |
|
- |
|
Onuscheck John Michael |
SVP & President, EMEA |
|
2012-02-12 |
4 |
D |
$5.93 |
$10,022 |
D/D |
(1,690) |
47,033 |
|
- |
|
Onuscheck John Michael |
SVP & President, EMEA |
|
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,993 |
48,723 |
|
- |
|
Nanavaty Maulik |
SVP & Pres, Neuromodulation |
|
2012-02-12 |
4 |
D |
$5.93 |
$9,802 |
D/D |
(1,653) |
51,984 |
|
- |
|
Nanavaty Maulik |
SVP & Pres, Neuromodulation |
|
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,391 |
53,637 |
|
- |
|
Pedersen John B. |
Pres, Uro & Womens Health |
|
2012-02-12 |
4 |
D |
$5.93 |
$2,129 |
D/D |
(359) |
639 |
|
- |
|
Pedersen John B. |
Pres, Uro & Womens Health |
|
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
998 |
998 |
|
- |
|
Phalen Michael P. |
EVP & President, MedSurg |
|
2012-02-12 |
4 |
D |
$5.93 |
$6,974 |
D/D |
(1,176) |
46,054 |
|
- |
|
Phalen Michael P. |
EVP & President, MedSurg |
|
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,274 |
47,230 |
|
- |
|
Fitzgerald Joseph Michael |
SVP & President, CRM |
|
2012-02-12 |
4 |
D |
$5.93 |
$4,370 |
D/D |
(737) |
62,524 |
|
- |
|
Fitzgerald Joseph Michael |
SVP & President, CRM |
|
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,996 |
63,261 |
|
- |
|
Pierce David A |
SVP and President, Endoscopy |
|
2012-02-12 |
4 |
D |
$5.93 |
$6,837 |
D/D |
(1,153) |
2,061 |
|
- |
|
Pierce David A |
SVP and President, Endoscopy |
|
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,210 |
3,214 |
|
- |
|
Burns Brian R |
EVP - Global Quality & Reg Aff |
|
2012-02-12 |
4 |
D |
$5.93 |
$8,504 |
D/D |
(1,434) |
67,350 |
|
- |
|
Burns Brian R |
EVP - Global Quality & Reg Aff |
|
2012-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,993 |
68,784 |
|
- |
|
Dawkins Keith D |
Sr. VP, Chief Medical Officer |
|
2012-01-07 |
4 |
D |
$5.30 |
$20,527 |
D/D |
(3,873) |
54,818 |
|
- |
|
Dawkins Keith D |
Sr. VP, Chief Medical Officer |
|
2012-01-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,771 |
58,691 |
|
- |
|
Nicholas Nicholas J Jr |
Director |
|
2011-11-29 |
4 |
B |
$5.56 |
$55,600 |
I/I |
10,000 |
180,000 |
2.1 |
- |
|
Mario Ernest |
Director |
|
2011-11-28 |
4 |
B |
$5.40 |
$540,000 |
D/D |
100,000 |
407,304 |
2.39 |
- |
|
Bartlett Katharine T |
Director |
|
2011-11-28 |
4 |
B |
$5.42 |
$43,360 |
D/D |
8,000 |
29,708 |
2.39 |
- |
|
Mario Ernest |
Director |
|
2011-11-21 |
4 |
B |
$5.30 |
$132,500 |
D/D |
25,000 |
306,004 |
2.39 |
- |
|
Connors Nelda J |
Director |
|
2011-11-14 |
4 |
S |
$5.84 |
$14,600 |
D/D |
(2,500) |
0 |
|
- |
|
Pierce David A |
SVP and President, Endoscopy |
|
2011-11-04 |
4 |
S |
$5.77 |
$91,548 |
D/D |
(15,869) |
4 |
|
- |
|
Pucel Kenneth |
EVP, Global Ops & Technology |
|
2011-10-31 |
4 |
D |
$5.89 |
$12,522 |
D/D |
(2,126) |
90,724 |
|
- |
|
Pucel Kenneth |
EVP, Global Ops & Technology |
|
2011-10-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,500 |
92,850 |
|
- |
|
1828 Records found
|
|
Page 24 of 74 |
|
|